Skip to main content
Erschienen in: Clinical and Translational Oncology 1/2022

24.06.2021 | Research Article

Isolated cancer stem cells from human liver cancer: morphological and functional characteristics in primary culture

verfasst von: M. Hu, M. Li, H. Huang, C. Lu

Erschienen in: Clinical and Translational Oncology | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Abstract

Background

Primary liver cancer cells (PLCs) could more directly simulate the human tumor microenvironment. Compared with liver cancer cell lines, PLCs could reflect the human situation. As in previous studies, tumor stem cells were a small number of cancer cells in the microenvironment and considered to be one of the origins of liver cancer. This study aimed to screen stem cells in PLCs, analyze their biological characteristics, propose the possibility that liver cancer originated from stem cells.

Methods

Liver cancer tissues of 17 patients were taken from the Affiliated Hospital of Guangdong Medical College, and PLCs were isolated by tissue slice method. The proliferation, tumor formation in nude mice, stem protein expression of PLCs were observed. C-kit+ liver cancer cells were screened and their biological characteristics were analyzed.

Results

PLCs could be stably passaged. Transmission electron microscopy indicated that the nucleus was irregular, there were many mitochondria, and the endoplasmic reticulum was irregularly distributed. PLCs could express E-Cadherin, Oct-4, β-Catenin, Sox2, CD326, C-kit, GPC3, Nanog. The proliferation curve of PLCs and Hep3B cells were similar, and they all could form tumors in nude mice. Flow-sorted C-kit+ PLCs, as well as C-kit+ Hep3B cells could highly express Bmi1, Sox2, Oct4, Notch1, Nanog, C-kit, β-Catenin, Smo, Nestin, ABCG2, ABCB1. And they also could clone and form tumors in vivo. But C-kit+ PLCs were more sensitive to chemotherapy drugs than C-kit+ liver cancer cell lines.

Conclusion

C-kit+ PLCs had the characteristics of tumor stem cells and were more sensitive to chemotherapy drugs.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Bray F, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.CrossRef Bray F, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.CrossRef
2.
3.
Zurück zum Zitat Yarchoan M, et al. Recent developments and therapeutic strategies against hepatocellular carcinoma. Can Res. 2019;79(17):4326–30.CrossRef Yarchoan M, et al. Recent developments and therapeutic strategies against hepatocellular carcinoma. Can Res. 2019;79(17):4326–30.CrossRef
4.
Zurück zum Zitat Forner A, et al. Treatment of intermediate-stage hepatocellular carcinoma. Nat Rev Clin Oncol. 2014;11(9):525–35.PubMedCrossRef Forner A, et al. Treatment of intermediate-stage hepatocellular carcinoma. Nat Rev Clin Oncol. 2014;11(9):525–35.PubMedCrossRef
5.
Zurück zum Zitat Shimokawa M, et al. Visualization and targeting of LGR5(+) human colon cancer stem cells. Nature. 2017;545(7653):187–92.PubMedCrossRef Shimokawa M, et al. Visualization and targeting of LGR5(+) human colon cancer stem cells. Nature. 2017;545(7653):187–92.PubMedCrossRef
6.
Zurück zum Zitat Lopez-Lazaro M. The stem cell division theory of cancer. Crit Rev Oncol Hematol. 2018;123:95–113.PubMedCrossRef Lopez-Lazaro M. The stem cell division theory of cancer. Crit Rev Oncol Hematol. 2018;123:95–113.PubMedCrossRef
7.
Zurück zum Zitat Raggi C, et al. Cancer stem cells and tumor-associated macrophages: a roadmap for multitargeting strategies. Oncogene. 2016;35(6):671–82.PubMedCrossRef Raggi C, et al. Cancer stem cells and tumor-associated macrophages: a roadmap for multitargeting strategies. Oncogene. 2016;35(6):671–82.PubMedCrossRef
9.
10.
11.
Zurück zum Zitat Blair A, et al. Lack of expression of Thy-1 (CD90) on acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo. Blood. 1997;89(9):3104–12.PubMedCrossRef Blair A, et al. Lack of expression of Thy-1 (CD90) on acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo. Blood. 1997;89(9):3104–12.PubMedCrossRef
12.
Zurück zum Zitat Zhou L, et al. Edmondson–Steiner grade: a crucial predictor of recurrence and survival in hepatocellular carcinoma without microvascular invasion. Pathol Res Pract. 2017;213(7):824–30.PubMedCrossRef Zhou L, et al. Edmondson–Steiner grade: a crucial predictor of recurrence and survival in hepatocellular carcinoma without microvascular invasion. Pathol Res Pract. 2017;213(7):824–30.PubMedCrossRef
14.
Zurück zum Zitat Singh SK, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003;63(18):5821–8.PubMed Singh SK, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003;63(18):5821–8.PubMed
15.
Zurück zum Zitat Collins AT, et al. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 2005;65(23):10946–51.PubMedCrossRef Collins AT, et al. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 2005;65(23):10946–51.PubMedCrossRef
16.
17.
Zurück zum Zitat Sia D, et al. Liver cancer cell of origin, molecular class, and effects on patient prognosis. Gastroenterology. 2017;152(4):745–61.PubMedCrossRef Sia D, et al. Liver cancer cell of origin, molecular class, and effects on patient prognosis. Gastroenterology. 2017;152(4):745–61.PubMedCrossRef
19.
Zurück zum Zitat Oikawa T. Cancer stem cells and their cellular origins in primary liver and biliary tract cancers. Hepatology. 2016;64(2):645–51.PubMedCrossRef Oikawa T. Cancer stem cells and their cellular origins in primary liver and biliary tract cancers. Hepatology. 2016;64(2):645–51.PubMedCrossRef
20.
Zurück zum Zitat Dickinson BT, et al. Molecular markers for colorectal cancer screening. Gut. 2015;64(9):1485–94.PubMedCrossRef Dickinson BT, et al. Molecular markers for colorectal cancer screening. Gut. 2015;64(9):1485–94.PubMedCrossRef
21.
Zurück zum Zitat Lennartsson J, Ronnstrand L. Stem cell factor receptor/c-Kit: from basic science to clinical implications. Physiol Rev. 2012;92(4):1619–49.PubMedCrossRef Lennartsson J, Ronnstrand L. Stem cell factor receptor/c-Kit: from basic science to clinical implications. Physiol Rev. 2012;92(4):1619–49.PubMedCrossRef
22.
Zurück zum Zitat Ashman LK, Griffith R. Therapeutic targeting of c-KIT in cancer. Expert Opin Investig Drugs. 2013;22(1):103–15.PubMedCrossRef Ashman LK, Griffith R. Therapeutic targeting of c-KIT in cancer. Expert Opin Investig Drugs. 2013;22(1):103–15.PubMedCrossRef
23.
Zurück zum Zitat Liu Q, et al. c-kit(+) cells adopt vascular endothelial but not epithelial cell fates during lung maintenance and repair. Nat Med. 2015;21(8):866–8.PubMedCrossRef Liu Q, et al. c-kit(+) cells adopt vascular endothelial but not epithelial cell fates during lung maintenance and repair. Nat Med. 2015;21(8):866–8.PubMedCrossRef
24.
Zurück zum Zitat Khosla R, et al. EpCAM+ liver cancer stem-like cells exhibiting autocrine wnt signaling potentially originate in cirrhotic patients. Stem Cells Transl Med. 2017;6(3):807–18.PubMedPubMedCentralCrossRef Khosla R, et al. EpCAM+ liver cancer stem-like cells exhibiting autocrine wnt signaling potentially originate in cirrhotic patients. Stem Cells Transl Med. 2017;6(3):807–18.PubMedPubMedCentralCrossRef
26.
Zurück zum Zitat Dong L, et al. The special stemness functions of Tbx3 in stem cells and cancer development. Semin Cancer Biol. 2019;57:105–10.PubMedCrossRef Dong L, et al. The special stemness functions of Tbx3 in stem cells and cancer development. Semin Cancer Biol. 2019;57:105–10.PubMedCrossRef
27.
Zurück zum Zitat Li L, Neaves WB. Normal stem cells and cancer stem cells: the niche matters. Cancer Res. 2006;66(9):4553–7.PubMedCrossRef Li L, Neaves WB. Normal stem cells and cancer stem cells: the niche matters. Cancer Res. 2006;66(9):4553–7.PubMedCrossRef
28.
Zurück zum Zitat Lapidot T, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994;367(6464):645–8.PubMedCrossRef Lapidot T, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994;367(6464):645–8.PubMedCrossRef
30.
Zurück zum Zitat Ishizawa K, et al. CD45(+)CD326(+) cells are predictive of poor prognosis in non-small cell lung cancer patients. Clin Cancer Res. 2019;25(22):6756–63.PubMedCrossRef Ishizawa K, et al. CD45(+)CD326(+) cells are predictive of poor prognosis in non-small cell lung cancer patients. Clin Cancer Res. 2019;25(22):6756–63.PubMedCrossRef
31.
Zurück zum Zitat Wang JR, et al. ESA-UbiSite: accurate prediction of human ubiquitination sites by identifying a set of effective negatives. Bioinformatics. 2017;33(5):661–8.PubMedCrossRef Wang JR, et al. ESA-UbiSite: accurate prediction of human ubiquitination sites by identifying a set of effective negatives. Bioinformatics. 2017;33(5):661–8.PubMedCrossRef
32.
Zurück zum Zitat Hintermann E, et al. Upregulation of matrilin-2 expression in murine hepatic stellate cells during liver injury has no effect on fibrosis formation and resolution. Liver Int. 2015;35(4):1265–73.PubMedCrossRef Hintermann E, et al. Upregulation of matrilin-2 expression in murine hepatic stellate cells during liver injury has no effect on fibrosis formation and resolution. Liver Int. 2015;35(4):1265–73.PubMedCrossRef
34.
Zurück zum Zitat Castelli G, Pelosi E, Testa U. Liver cancer: molecular characterization, clonal evolution and cancer stem cells. Cancers (Basel). 2017;9(9):127.CrossRef Castelli G, Pelosi E, Testa U. Liver cancer: molecular characterization, clonal evolution and cancer stem cells. Cancers (Basel). 2017;9(9):127.CrossRef
35.
Zurück zum Zitat Yin S, et al. CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int J Cancer. 2007;120(7):1444–50.PubMedCrossRef Yin S, et al. CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int J Cancer. 2007;120(7):1444–50.PubMedCrossRef
36.
Zurück zum Zitat Ma S, et al. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology. 2007;132(7):2542–56.PubMedCrossRef Ma S, et al. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology. 2007;132(7):2542–56.PubMedCrossRef
37.
Zurück zum Zitat Yang ZF, et al. Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell. 2008;13(2):153–66.PubMedCrossRef Yang ZF, et al. Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell. 2008;13(2):153–66.PubMedCrossRef
38.
Zurück zum Zitat Yamashita T, et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology. 2009;136(3):1012–24.PubMedCrossRef Yamashita T, et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology. 2009;136(3):1012–24.PubMedCrossRef
39.
Zurück zum Zitat Chen Y, et al. CD133(+)EpCAM(+) phenotype possesses more characteristics of tumor initiating cells in hepatocellular carcinoma Huh7 cells. Int J Biol Sci. 2012;8(7):992–1004.PubMedPubMedCentralCrossRef Chen Y, et al. CD133(+)EpCAM(+) phenotype possesses more characteristics of tumor initiating cells in hepatocellular carcinoma Huh7 cells. Int J Biol Sci. 2012;8(7):992–1004.PubMedPubMedCentralCrossRef
40.
Zurück zum Zitat Terris B, Cavard C, Perret C. EpCAM, a new marker for cancer stem cells in hepatocellular carcinoma. J Hepatol. 2010;52(2):280–1.PubMedCrossRef Terris B, Cavard C, Perret C. EpCAM, a new marker for cancer stem cells in hepatocellular carcinoma. J Hepatol. 2010;52(2):280–1.PubMedCrossRef
41.
Zurück zum Zitat Yarden Y, et al. Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J. 1987;6(11):3341–51.PubMedPubMedCentralCrossRef Yarden Y, et al. Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J. 1987;6(11):3341–51.PubMedPubMedCentralCrossRef
42.
Metadaten
Titel
Isolated cancer stem cells from human liver cancer: morphological and functional characteristics in primary culture
verfasst von
M. Hu
M. Li
H. Huang
C. Lu
Publikationsdatum
24.06.2021
Verlag
Springer International Publishing
Erschienen in
Clinical and Translational Oncology / Ausgabe 1/2022
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-021-02667-w

Weitere Artikel der Ausgabe 1/2022

Clinical and Translational Oncology 1/2022 Zur Ausgabe

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

13.05.2024 Pankreaskarzinom Nachrichten

Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.